<p>On June 21, Eli Lilly announced the results of the Phase III study of the once-daily oral small molecule GLP-1 drug orforglipron. The results showed that this investigational drug achieved an average reduction in hemoglobin A1c of 1.3% to 1.6% in adult patients with type 2 diabetes across all dosage groups, with improvements observable within four weeks of treatment. Additionally, the high-dose group achieved an average weight loss of 7.3 kg by week 40. Eli Lilly stated that it expects to submit a marketing application for orforglipron for weight management to global regulatory authorities by the end of this year, and anticipates submitting its application for the treatment of type 2 diabetes in 2026</p>

<p>Eli Lilly announced the Phase III study results of the oral small molecule GLP-1 drug orforglipron on June 21. The study showed that the drug reduced hemoglobin A1c by an average of 1.3% to 1.6% in patients with type 2 diabetes, with improvements visible within four weeks. The high-dose group achieved an average weight loss of 7.3 kg by week 40. Eli Lilly plans to submit a marketing application for orforglipron to global regulatory agencies by the end of the year, with an application for the treatment of type 2 diabetes expected in 2026</p>

Eli Lilly announces phase III study results of oral small molecule GLP-1 drug